FDA Centers Will Change To Meet Requirements Of Personalized Medicine - Von Eschenbach
This article was originally published in The Pink Sheet Daily
Executive Summary
Acting commissioner says agency must streamline regulatory decision making for combination diagnostic and therapeutic products.
You may also be interested in...
Part D Data Sharing Could Help Enable Assessment Of Drug Coverage’s Impact On Overall Heath Care Costs – CMS
Proposed regulation would permit use of payment data for research and “public health functions.”
Biomarkers Consortium To Investigate Lung Cancer, Non-Hodgkins Lymphoma
Public-private biomedical research partnership will also investigate biomarkers in major depressive disorder, diabetes and pre-diabetes.
Patents, Payment, Science: Triple Challenge To Pharmacogenetic Innovation
Current and former Roche scientists discuss personalized medicine.